Advances in clinical application of ruxolitinib for hematologic malignancies / 中国肿瘤临床

ABSTRACT

Because the pathogenesis of some hematologic malignancies (e.g., myeloproliferative disease, MPN; acute leukemia, AL;multiple myeloma, MM; and (hemophagocytic syndrome, HPS) involve abnormalities in the JAK/STAT pathway, a series of drugs that target the JAK/STAT pathway has been the subject of clinical trials. Ruxolitinib (also known as INCB018424), an inhibitor of the JAK1/2 pathway, was approved as the treatment choice for myelofibrosis (MF) and polycythemia vera (PV) by the U.S. Food and Drug Adminis-tration (FDA) in 2011. Moreover, some studies have shown that ruxolitinib can achieve exciting clinical results in the treatment of AL, MM, and HLH, making it a potential choice of treatment for those diseases. In this review, we summarize the advances in ruxolitinib therapy with regard to research and clinical results for the above-mentioned hematologic malignancies.